AbbVie Inc. (ABBV) is a renowned global pharmaceutical company with a market cap of $384.6 billion. Headquartered in Illinois, AbbVie focuses on developing and marketing advanced therapies in various areas, including immunology, oncology, neuroscience, and aesthetics. The company is well-known for its blockbuster drugs like Humira and newer growth drivers such as Skyrizi and Rinvoq.
The drug giant is gearing up to announce its fiscal first-quarter earnings for 2026 on Friday, Apr. 24. Analysts are expecting ABBV to report a profit of $3.01 per share, representing a 22.4% increase from the year-ago quarter’s $2.46 per share. AbbVie has a track record of surpassing Wall Street’s EPS estimates in its previous four quarterly reports.
Looking ahead, analysts project ABBV to report an EPS of $14.59 for the current year, a 45.9% increase from fiscal 2025’s $10. Additionally, the company’s EPS is forecasted to rise by 10.6% year over year to $16.14 in fiscal 2027.
Despite facing challenges, ABBV stock has shown resilience, climbing 4.2% over the past 52 weeks. While this growth lags behind the S&P 500 Index’s 16.7% gains, it surpasses the State Street Health Care Select Sector SPDR Fund’s 3.1% returns during the same period.
Recently, AbbVie made headlines with its new dermatology research presented at the 2026 American Academy of Dermatology Annual Meeting. The company showcased 24 abstracts highlighting the strong clinical and real-world evidence for its key drugs, risankizumab and upadacitinib. The data demonstrated sustained efficacy, long-term safety, and improved quality of life in treating immune-mediated skin diseases, reinforcing AbbVie’s position as a leader in dermatology.
Analysts’ consensus opinion on ABBV stock leans moderately bullish, with a “Moderate Buy” rating overall. Out of 31 analysts covering the stock, 17 recommend a “Strong Buy,” two suggest a “Moderate Buy,” and 12 give a “Hold” rating. The average analyst price target for ABBV is $249.82, indicating a potential upside of 16.2% from current levels.
In conclusion, AbbVie Inc. continues to showcase its strength in the pharmaceutical industry with innovative therapies and strong financial performance. Investors and analysts alike are optimistic about the company’s future prospects, making ABBV stock a compelling investment opportunity.
